Jamie Smith
Media Relations Manager
Email: jamie.smith@molnlycke.com
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.

Mikkeli photo credit: Pihla Liukkonen, Kontrastia
Building on recent expansion announcements in Brunswick, USA, and Changshu, China, the coordinated investments reflect Mölnlycke’s continued focus on meeting growing demand for advanced wound care solutions and helping to free patients from the burden of wounds, while optimising its manufacturing footprint.
At its Mikkeli site, Mölnlycke is investing in expanded sterilisation and production capabilities. The programme doubles sterilisation capacity and introduces an advanced ‘soft cycle’ process, ensuring gentler product treatment and more sustainable manufacturing processes.
This expansion also increases manufacturing capacity by around 100 million units annually, an increase of nearly 50%, supported by a new production line with automated inline packaging and cartoning to improve efficiency and handling.
In parallel, Mölnlycke has inaugurated new state-of-the-art clean room and packaging facilities in Oldham, expanding UK manufacturing capacity.
Moreover, by bringing sterilisation closer to production, Mölnlycke expects to shorten lead times by around one week while reducing transportation distances and emissions, strengthening supply chain resilience and environmental performance.

The investments in Mikkeli and Oldham are designed to operate as an integrated system, connecting and optimising how products are manufactured, sterilised and delivered, while strengthening collaboration and knowledge-sharing across sites.
“Together, these investments strengthen our global wound care manufacturing network and connect capabilities across sites, enabling us to scale efficiently, improve resilience and deliver sustainable growth,” says David Butler, Global Vice President, Operations Wound Care at Mölnlycke.
For more information, please contact:

Media Relations Manager
Email: jamie.smith@molnlycke.com
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.
Gothenburg, Sweden. 17 September 2025. A new narrative review published in the current issue of Journal of Patient Safety, titled ’Putting Patients at Risk: The Effect of Health Care Provider Burnout on Patient Care in the Operating Room’ reveals alarmingly high levels of burnout among healthcare workers in operating rooms (ORs) and warns of the serious implications for staff well-being, care quality and ultimately patient safety.
Gothenburg, Sweden. 21 August 2025. Mölnlycke®, a world-leading MedTech company, has once again been recognised as a global sustainability leader, earning the prestigious EcoVadis Platinum medal for the second year in a row.
Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.